Trevi Therapeutics, Inc. Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss
Trevi Therapeutics, Inc. (TRVI) reported Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2024-05-07
- Trevi Therapeutics, Inc. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-03-31 was $0.00.
- Trevi Therapeutics, Inc. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-03-31 was $0.00.
- Trevi Therapeutics, Inc. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $0.00.
- Trevi Therapeutics, Inc. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was $0.00.
| Period end | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $0.00 10-K · filed 2024-03-20 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |